| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | Indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
| Assessment Process | |
| Rapid review commissioned | 10/10/2012 |
| Rapid review completed | 22/10/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 01/08/2013 |
| NCPE assessment completed | 31/12/2013 |
| NCPE assessment outcome | Reimbursement not recommended at this time |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
